authID’s PrivacyKey™ Named “Best Digital Trust Solution - ID Verification & Authentication” in 2025 PayTech Awards
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alnylam (Nasdaq: ALNY) reported post hoc analyses from the HELIOS-B Phase 3 study of AMVUTTRA (vutrisiran) showing reductions in gastrointestinal (GI) adverse events and reinforcing monotherapy efficacy.
Key findings: a 42% lower GI event rate overall, 37% lower in vutrisiran monotherapy, and 49% lower in patients on tafamidis at baseline; individual symptoms (diarrhea, nausea, vomiting) fell >50% with rate ratios as low as 0.16. A censored monotherapy analysis showed a 32% reduction in the primary composite endpoint through 36 months (HR 0.68; 95% CI 0.49–0.95; p=0.022), consistent with the primary monotherapy HR 0.67 (p=0.016). AMVUTTRA has >8,000 patient‑years exposure and recent approvals in multiple regions.
Positive
- Overall GI event rate reduced by 42% versus placebo
- Vutrisiran monotherapy GI events reduced by 37%
- Baseline tafamidis group GI events reduced by 49%
- Censored monotherapy: primary endpoint risk ↓ 32% (HR 0.68; p=0.022)
- AMVUTTRA supported by > 8,000 patient‑years exposure
Negative
- AMVUTTRA treatment reduces serum vitamin A; supplementation required
- Common adverse reactions include pain in extremity 15% and arthralgia 11%
- Tafamidis was initiated in 21.5% of monotherapy patients (median ~18 months)
Details
News Market Reaction – AUID
On Dec 10, the day this news came out, AUID closed 5.69% below the previous close.
Data tracked by StockTitan Argus for the Dec 10 session.
Key Figures
- Lower GI event rate (overall)
- 42% lower rate vs placebo
- HELIOS-B post hoc analysis overall population
- Lower GI event rate (monotherapy)
- 37% lower rate vs placebo
- HELIOS-B vutrisiran monotherapy group
- Lower GI event rate (tafamidis baseline)
- 49% lower rate vs placebo
- HELIOS-B baseline tafamidis group
- GI symptom reduction
- >50% reduction
- Diarrhea, nausea, vomiting across all three study populations
- Hazard ratio (primary endpoint)
- HR 0.68 (95% CI: 0.49–0.95)
- Censored monotherapy population, all-cause mortality & CV events through 36 months
- P-value primary endpoint
- p=0.022
- Risk reduction for all-cause mortality and recurrent CV events
- Tafamidis initiation
- 21.5% of monotherapy patients
- HELIOS-B censored monotherapy analysis; median 18 months to initiation
- Prior HR result
- HR 0.67 (95% CI: 0.49–0.93); p=0.016
- Primary monotherapy analysis including later tafamidis initiators
Historical Context
-
New deployment of PrivacyKey for biometric security in correctional education.
-
Closing of $3.675M registered direct offering at $1.35–$1.71 per share.
-
Pricing of $3.675M registered direct equity and pre-funded warrant deal.
-
Joining NVIDIA Connect Program to advance GPU-powered biometric AI security.
-
Launch of authID Mandate framework for governance of agentic AI identities.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
transthyretin-mediated amyloidosis medical
rnai therapeutic medical
hazard ratio medical
confidence interval medical
kansas city cardiomyopathy questionnaire medical
polyneuropathy medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
PrivacyKey™ recognized for delivering fast, secure, privacy-first biometric authentication that enhances trust across digital payments
DENVER, Dec. 10, 2025 (GLOBE NEWSWIRE) -- authID (Nasdaq: AUID), a leading provider of biometric identity verification and authentication solutions, today announced that its flagship product PrivacyKey™ has been named Best Digital Trust Solution – ID Verification & Authentication by Fintech Futures for the 2025 PayTech Awards, which celebrate excellence and innovation in the global payments and fintech industry.
PrivacyKey delivers sub-second, deterministic biometric authentication with a privacy-first approach that ensures users are who they claim to be, while safeguarding sensitive data and meeting global compliance standards. By combining liveness detection, advanced biometric matching, and a patented, privacy-preserving architecture, PrivacyKey enhances security across the entire digital transaction lifecycle. From account creation and onboarding to payments approvals and ongoing user verification, PrivacyKey offers consumers and enterprises a seamless, fraud-proof experience.
“We are honored that PrivacyKey has been recognized by the PayTech Awards as a leading digital trust solution. At authID, our mission is to eliminate the trade-off between security and convenience by making biometric identity authentication seamless for users and highly effective for enterprises,” said authID CEO Rhon Dauguro. “This recognition validates the impact of PrivacyKey in helping financial institutions and payments providers combat fraud, protect consumers, and strengthen trust. We look forward to continuing to set the standard for secure, frictionless authentication in the payments industry and beyond.”
PrivacyKey features critical key-management capabilities that ensure the highest level of user protection and privacy. Enterprises can rotate and revoke keys with ease, ensuring the keys are accessible only to authorized users, providing a level of security not available through any other vendor. PrivacyKey represents the ultimate in data privacy protection as well as compliance, given that no facial biometrics are stored.
PrivacyKey’s encrypted public keys are minted when users are validated by authID’s ProofTM solution, the fastest and more accurate biometric IDV platform in the industry. The unique architecture and value of PrivacyKey is the reason it has been chosen by many industry leaders for their identity assurance component. This has led to authID being embedded in technology offered for customers of NEC Networks and System Integration Corporation (NESIC), Prove, and MajorKey, and available in the marketplaces for Zendesk and Nvidia, acting as a critical, easily-integrated option for biometric verification in front of those platforms. PrivacyKey replaces the tokens, facial images, or other vulnerable, device-bound artifacts utilized by other vendors, ensuring privacy protection and industry-leading performance and accuracy.
In addition to its value for human verification, PrivacyKey is a critical part of authID’s IDX platform for securing distributed workforces. It also serves to power the authID Mandate framework for Agentic AI security, by ensuring that AI agents can only be launched after being bound to the credentials of biometrically-verified sponsors, as described in our recent announcement.
“Being named the winner of the Paytech Awards for verification and authentication underscores our commitment to advancing digital trust,” commented Erick Soto, authID’s Chief Product Officer. “We will continue to redefine how enterprises and consumers protect themselves in an increasingly complex threat landscape, while helping organizations build their businesses by onboarding only trusted individuals.”
The full list of 2025 PayTech Award Winners can be found here.
About authID
authID® (Nasdaq: AUID) ensures enterprises “Know Who's Behind the Device™” for every customer or employee login and transaction through its easy-to-integrate, patented, biometric identity platform. authID quickly and accurately verifies a user's identity, eliminating any assumption of 'who' is behind a device to prevent cybercriminals from compromising account openings or taking over accounts. Leveraging a 1-in-1-billion False Positive Rate for the highest level of assurance, coupled with industry-leading speed and privacy-preserving technology, authID provides the most secure digital identity experience. Our IDX platform secures the distributed workforce of employees, contractors, and vendors, as well as bringing authorization and accountability for AI agents through our authID Mandate framework. By creating a biometric root of trust for each user, authID stops fraud at onboarding, detects and stops deepfakes, eliminates password risks and costs, and provides the fastest, frictionless, and most accurate user identity experience in the industry. For more information, please visit www.authID.ai.
authID Investor Relations
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.